Results 51 to 60 of about 21,205,447 (258)

External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification

Frontiers in Oncology
IntroductionIn the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.MethodsResected pT1/2 PM patients were ...
Zheng Liu, Zheng Liu, Zheng Liu, Zheng Liu, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Yun Li, Yun Li, Wenhan Weng, Wenhan Weng   +11 more
doaj   +1 more source

Long Non-Coding RNA CAR10 Facilitates Non-Small Cell Lung Cancer Cell Migration and Invasion by Modulating the miR-892a/GJB2 Pathway

Cancer Management and Research, 2021
Shanshan Li1 *,* Yize Liu2 *,* Guanzhen Qiu,2 Yinzhou Luo,2 Lan Luan,3 Tiance Xu,4 Yong Wang,2,5 Shuyue Xia1,6 1Respiratory Department, Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning, 110024, People’s Republic of China;
Li S, Liu Y, Qiu G, Luo Y, Luan L, Xu T, Wang Y, Xia S   +7 more
doaj  

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients
with Stage IB-IIIB Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer
Background and objective Neoadjuvant immunochemotherapy has emerged as an indispensable therapeutic modality for non-small cell lung cancer (NSCLC).
Zihao LI, Xin WANG, Yulong WANG, Zhuoer CUI, Xin WANG, Xiao LI, Guanchao JIANG, Xun WANG   +7 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Caucasian validation of downstaging from IIB to IIA in T1N1M0 patients within the 9th edition of the non‐small cell lung cancer tumor‐node‐metastasis staging

Cancer Medicine
Background The 9th edition of the lung cancer tumor‐node‐metastasis (TNM) staging introduced adjustments, including the reclassification of T1N1M0 patients from stage IIB to IIA. This update used data mostly from Asian populations.
Jingsheng Cai, Yun Li, Feng Yang
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Comparison of platinum and non-platinum based regimens in the treatment of small cell lung cancer

, 2023
Small cell lung cancer, and lung cancer in general, remains one of the most impactful public health issues in the modern age due to its high morbidity and mortality.
Benyarko, Ato
core  

Chinese Expert Consensus on Assessment and Clinical Application of 
Tertiary Lymphoid Structure for Non-small Cell Lung Cancer (2025 Version)

Chinese Journal of Lung Cancer
The tertiary lymphoid structure (TLS) plays a crucial role in the tumor microenvironment, influencing tumor development and progression. As an emerging biomarker for predicting the prognosis and treatment response in cancer patients, TLS has received ...
Lung Cancer Collaboration Group of Tumor Pathology Committee of Chinese Anti-Cancer Association, Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology   +1 more
doaj   +1 more source